Publications by authors named "Jean Luc Houeto"
Article Synopsis
- * It found that GTS patients exhibited higher firing rates and burst activity, while DYS patients showed more pauses and burst frequency, highlighting distinct neuronal activity patterns between the two disorders.
- * The research suggests a need for further studies on neuronal behavior in the GPi to improve DBS techniques and tailor treatments for better clinical outcomes in patients with hyperkinetic movement disorders.
Psychiatric symptoms are common in neurodevelopmental movement disorders, including some types of dystonia. However, research has mainly focused on motor manifestations and underlying circuits. Myoclonus-dystonia is a rare and homogeneous neurodevelopmental condition serving as an illustrative paradigm of childhood-onset dystonias, associated with psychiatric symptoms.
View Article and Find Full Text PDFArticle Synopsis
- The study explores myoclonus dystonia caused by a variant in the SGCE gene, focusing on the microarchitectural brain abnormalities linked to this rare condition.
- Researchers compared the brain structures of 18 MYC/DYT-SGCE patients with 24 healthy volunteers using advanced imaging techniques to assess neurite organization.
- Results indicate that patients exhibited changes in cerebellar structure, with specific alterations correlating to the severity of dystonia, while no links were found between myoclonus severity and the microarchitectural measurements.
Article Synopsis
- This study investigates the non-motor aspects of myoclonus dystonia, focusing on the sense of agency, which is how individuals perceive control over their actions, and how disruptions in this sense can affect movement disorders.* -
- The research compared 19 patients with myoclonus dystonia (stemming from a specific genetic variant) to 24 healthy participants, revealing that the patients had a significant impairment in their explicit sense of agency, while their implicit sense remained unaffected.* -
- Neuroimaging analyses showed structural and functional abnormalities in the cerebellum and its connectivity with the pre-supplementary motor area, suggesting these brain regions play a crucial role in the altered sense of agency in patients with my
Background: Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease.
Methods: In this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson's disease. Participants in whom Parkinson's disease was diagnosed less than 3 years earlier, who were receiving a stable dose of medications to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by a 2-month washout period.
Amantadine use in the French prospective NS-Park cohort.
J Neural Transm (Vienna)
July 2024
Article Synopsis
- The study aimed to evaluate the use of amantadine in patients with Parkinson's disease (PD) and its effectiveness in treating levodopa-induced dyskinesia (LIDs).
- It found that 12.6% of PD patients in the French NS-Park cohort were using amantadine, primarily younger patients with more severe symptoms and higher doses of levodopa.
- The results indicated that starting amantadine led to significant improvements in LIDs and motor fluctuations among new users compared to those who had never used the drug.
Article Synopsis
- The study explored the potential of bumetanide, a medication aimed at enhancing motor symptoms in Parkinson's disease by targeting GABA-ergic cells.
- It involved 44 participants in a 4-month trial comparing bumetanide to a placebo in conjunction with levodopa treatment.
- The results showed no significant improvement in motor symptoms between bumetanide and placebo groups, and bumetanide was poorly tolerated despite no major safety concerns.
Background: The long-term prognosis of impulsive compulsive disorders (ICD) remains poorly studied in Parkinson's disease (PD).
Objective: Evaluating the natural history of ICD and its impact on PD symptoms including cognition and treatment adjustments.
Materials And Methods: We assessed PD patients at baseline (BL) with (BL-ICD+) or without (BL-ICD-) ICD despite dopamine agonist (DA) exposure of > 300 mg levodopa-equivalent daily dose for > 12 months at baseline and after more than two years of follow-up.
Postoperative apathy is a frequent symptom in Parkinson's disease patients who have undergone bilateral deep brain stimulation of the subthalamic nucleus. Two main hypotheses for postoperative apathy have been suggested: (i) dopaminergic withdrawal syndrome relative to postoperative dopaminergic drug tapering; and (ii) direct effect of chronic stimulation of the subthalamic nucleus. The primary objective of our study was to describe preoperative and 1-year postoperative apathy in Parkinson's disease patients who underwent chronic bilateral deep brain stimulation of the subthalamic nucleus.
View Article and Find Full Text PDFBackground: Longitudinal measures of structural brain changes using MRI in relation to clinical features and progression patterns in PD have been assessed in previous studies, but few were conducted in well-defined and large cohorts, including prospective clinical assessments of both motor and non-motor symptoms.
Objective: We aimed to identify brain volumetric changes characterizing PD patients, and determine whether regional brain volumetric characteristics at baseline can predict motor, psycho-behavioral and cognitive evolution at one year in a prospective cohort of PD patients.
Methods: In this multicentric 1 year longitudinal study, PD patients and healthy controls from the MPI-R2* cohort were assessed for demographical, clinical and brain volumetric characteristics.
Correction: Association of Rare Genetic Variants in Opioid Receptors with Tourette Syndrome.
Tremor Other Hyperkinet Mov (N Y)
July 2023
Article Synopsis
- The article mentioned has been corrected to address previous errors identified in its content.
- The correction enhances the accuracy of the information for readers and researchers relying on the data.
- The DOI provided (10.5334/tohm.464) allows access to the updated and accurate version of the article.
Background: The EARLYSTIM trial demonstrated for Parkinson's disease patients with early motor complications that deep brain stimulation of the subthalamic nucleus (STN-DBS) and best medical treatment (BMT) was superior to BMT alone.
Objective: This prospective, ancillary study on EARLYSTIM compared changes in blinded speech intelligibility assessment between STN-DBS and BMT over 2 years, and secondary outcomes included non-speech oral movements (maximum phonation time [MPT], oral diadochokinesis), physician- and patient-reported assessments.
Methods: STN-DBS (n = 102) and BMT (n = 99) groups underwent assessments on/off medication at baseline and 24 months (in four conditions: on/off medication, ON/OFF stimulation-for STN-DBS).
Several postmortem studies have shown iron accumulation in the substantia nigra of Parkinson's disease patients. Iron concentration can be estimated via MRI-R mapping. To assess the changes in R occurring in Parkinson's disease patients compared to controls, a multicentre transversal study was carried out on a large cohort of Parkinson's disease patients (n = 163) with matched controls (n = 82).
View Article and Find Full Text PDFGenetic stratification of motor and QoL outcomes in Parkinson's disease in the EARLYSTIM study.
Parkinsonism Relat Disord
October 2022
Article Synopsis
- The study explores whether genetic variables can predict outcomes of subthalamic deep brain stimulation (STN-DBS) in patients with Parkinson's disease (PD).
- Researchers aimed to replicate an earlier finding that a specific genetic variant (SNCA rs356220) was linked to better STN-DBS responses and looked at additional genetic factors from recent genome-wide association studies (GWAS).
- Although the SNCA rs356220 variant didn't predict motor outcomes, it was associated with improved quality of life; other genetic markers showed predictive value for DBS outcomes, but polygenic risk scores were not useful in this context.
Background: Previous studies described a parkinsonian personality characterized as rigid, introverted, and cautious; however, little is known about personality traits in de novo Parkinson's disease (PD) patients and their relationships with motor and neuropsychiatric symptoms.
Objective: To investigate personality in de novo PD and explore its relationship with PD symptoms.
Methods: Using Cloninger's biosocial model, we assessed personality in 193 de novo PD patients.
Background: Subthalamic nucleus deep brain stimulation (STN-DBS) effectively treats motor symptoms and quality of life (QoL) of advanced and fluctuating early Parkinson's disease. Little is known about the relation between electrode position and changes in symptom control and ultimately QoL.
Objectives: The relation between the stimulated part of the STN and clinical outcomes, including the motor score of the Unified Parkinson's Disease Rating Scale (UPDRS) and the quality-of-life questionnaire, was assessed in a subcohort of the EARLYSTIM study.
Background: There are no effective treatments for multiple system atrophy (MSA).
Objective: The objective of this study was to assess the efficacy and safety of the serotonin reuptake inhibitor fluoxetine (40 mg/d) for the symptomatic treatment of MSA.
Methods: This was a double-blind, parallel-group, placebo-controlled, randomized trial in patients with "probable" MSA.
The transition from controlled drug use to drug addiction depends on an interaction between a vulnerable individual, their environment and a drug. Here we tested the hypothesis that conditions under which individuals live influence behavioral vulnerability traits and experiential factors operating in the drug taking environment to determine the vulnerability to addiction. The role of behavioral vulnerability traits in mediating the influence of housing conditions on the tendency to acquire cocaine self-administration was characterized in 48 rats housed in either an enriched (EE) or a standard (SE) environment.
View Article and Find Full Text PDFObjectives: Nucleus basalis of Meynert deep brain stimulation (NBM-DBS) has been proposed for patients with dementia. Here, we aim to assess the safety and effects of NBM-DBS in patients with Lewy body dementia (LBD), in a randomized, double-blind, crossover clinical trial.
Methods: Six patients with mild to moderate LBD (mean [SD] age, 62.
Background: Impact of subthalamic deep brain stimulation (DBS) on impulse control disorders (ICD) in Parkinson's disease (PD) remains controversial.
Objectives: The objectives of this study were to analyze the natural history of ICD between baseline and 1 year after subthalamic DBS in patients with PD and to identify predictive factors, taking into account the positions of the active contact and stimulation parameters.
Methods: We analyzed postoperative modifications of ICD based on the multicentric, prospective Predictive Factors and Subthalamic Stimulation in Parkinson's Disease cohort.
The EARLYSTIM Study compared deep brain stimulation (DBS) with best medical treatment (BMT) over 2-years, showing a between-group difference of 8.0 from baseline in favor of DBS in health-related quality of life (HRQoL), measured with the PDQ-39 SI (summary index). This study obtained complementary information about the importance of the change in HRQoL as measured by the PDQ-39, using anchor-based (Patient Global Impression of Change, PGIC) and distribution-based techniques (magnitude of change, effect size, thresholds, distribution of benefit) applied to the EARLYSTIM study data.
View Article and Find Full Text PDFArticle Synopsis
- Myoclonus-dystonia (MD) is a neurological syndrome involving muscle jerks and dystonia, often linked to mental health issues, caused by dysfunction in specific brain pathways.
- A study using the Stop Signal Task examined the reactive and proactive inhibitory control in MD patients, comparing those with and without deep brain stimulation treatment to healthy controls.
- Findings revealed that unoperated MD patients had impaired proactive inhibition, while those with deep brain stimulation had issues with reactive inhibition, indicating different effects on inhibitory control depending on the treatment status.
Article Synopsis
- Deep brain stimulation (DBS) shows significant improvements in social, occupational, and psychosocial functioning in younger Parkinson's disease (PD) patients compared to best medical therapy (BMT) over 24 months.* -
- Both DBS and BMT groups had similar work status at the start and end of the study, but the BMT group had a higher rate of patients unable to work at the 24-month mark.* -
- Apathy in patients may affect their perceived work ability, with discrepancies between physician assessments and patients' self-ratings noted in the study.*
microRNAs are small non-coding RNAs gaining interest for their potential roles as reliable biomarkers for the diagnosis and therapeutics of numerous pathologies, ranging from cancer to neurodegenerative or psychiatric disorders. Indeed, microRNAs are present in various accessible biofluids, including peripheral blood, and specific dysregulation of their expression may be associated with these different pathological conditions. microRNAs can be isolated from plasma or serum for sequencing with commercial kits.
View Article and Find Full Text PDF